As of 2026-04-10, the Intrinsic Value of Anavex Life Sciences Corp (AVXL) is -2.16 USD. This Anavex valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.04 USD, the upside of Anavex Life Sciences Corp is -170.90%.
Based on its market price of 3.04 USD and our intrinsic valuation, Anavex Life Sciences Corp (AVXL) is overvalued by 170.90%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -2.16 - -2.16 | -2.16 | -170.90% |
| P/E | (8.05) - (9.41) | (8.99) | -395.6% |
| DDM - Stable | (2.93) - (13.44) | (8.19) | -369.3% |
| DDM - Multi | (0.80) - (3.02) | (1.28) | -142.1% |
| Market Cap (mil) | 281.72 |
| Beta | 1.68 |
| Outstanding shares (mil) | 92.67 |
| Enterprise Value (mil) | 149.97 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.59% |
| Cost of Debt | 5.00% |
| WACC | 7.79% |